Homologous recombination repair gene alterations in prostate cancer: expert recommendations for genetic and biomarker testing
PURPOSE OF REVIEW: Homologous recombination repair (HRR) gene alterations are associated with genomic instability and more aggressive prostate cancer (PCa) leading to worse clinical outcomes. poly(ADP-ribose) polymerase inhibitors have demonstrated significant clinical benefit in patients with HRR-altered tumors, and international guidelines now recommend HRR testing. Nevertheless, real-world adoption of this testing remains inconsistent across healthcare systems. To address this gap, we developed expert-driven, practical recommendations for integrating HRR testing into clinical practice for patients with PCa. RECENT FINDINGS: The panel developed consensus recommendations addressing the optimal timing of HRR testing, patient selection criteria, appropriate use of genetic and biomarker testing platforms, and interpretation of test results. Hypothetical case studies illustrated application in clinical settings. These recommendations are evidence-based but reflect expert opinion and should be tailored to local circumstances. No statistical analyses were performed; generalizability may be influenced by differences between healthcare systems. SUMMARY: These expert consensus recommendations provide practical guidance on facilitating the broader and more consistent implementation of HRR testing in men with PCa. Wider adoption of such testing may enable more personalized treatment approaches and lead to improved patient outcomes.
Authors
- Marc‐Oliver Grimm (ORCID: https://orcid.org/0000-0003-3084-8654)
- Joshua Michael Lang (ORCID: https://orcid.org/0000-0002-0943-8872)
- Erik Briers (ORCID: https://orcid.org/0000-0002-7267-8449)
- Todd Matthew Morgan (ORCID: https://orcid.org/0000-0002-1140-0603)
- Niven Mehra (ORCID: https://orcid.org/0000-0002-4794-1831)
- Shahrokh F. Shariat
- Shel Liang
- Alexander W. Wyatt
Institutions
- Al-Ahliyya Amman University (JO)
- University of Wisconsin–Madison (US)
- University of British Columbia (CA)
- Pfizer (United States) (US)
- Charles University (CZ)
- University of Michigan (US)
- Radboud University Medical Center (NL)
- University of Wisconsin Carbone Cancer Center (US)
- Jena University Hospital (DE)
- Weill Cornell Medicine (US)
- Vancouver Prostate Centre (CA)
- Medical University of Vienna (AT)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Current Opinion in Urology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1097/mou.0000000000001465
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00